A Phase 2 interventional study of BPL-003 in Treatment Resistant Depression, sponsored by Beckley Psytech Limited. Recruiting at 3 sites in United Kingdom. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-07-06.
Sponsored by Beckley Psytech Limited (part of Eli Lilly and Company) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies in Depressive Disorder, Treatment-Resistant with a site in United Kingdom — 6 open to participants now, 7 under way, 2 of them phase 3. Depressive Disorder, Treatment-Resistant · United Kingdom.
Among the 26 studies in Depressive Disorder, Treatment-Resistant with a site in United Kingdom, this one is the 13th largest by planned enrollment of the 21 interventional ones that give a count, is one of 3 that started in 2023, is one of 6 in phase 2, and was the 18th registered.
448 studies on the registry are indexed under Depressive Disorder, Treatment-Resistant; 147 are open to participants now.
Browse Depressive Disorder, Treatment-Resistant studies →6 of the 26 studies in Depressive Disorder, Treatment-Resistant with a site in United Kingdom are open now. Recruiting first, the newest first:
Alto Neuroscience · Sites in United Kingdom, United States
Ages 18–75
Dr. Inge Winter · Sites in United Kingdom, Austria, Germany and 3 more countries
Ages 18–65
University of Oxford · Sites in United Kingdom
Ages 18–70
LivaNova · Sites in United Kingdom, Austria, Belgium and 1 more country
Ages 18+
University of Oxford · Sites in United Kingdom
Ages 18+
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 114 Depressive Disorder, Treatment-Resistant studies recruiting now, 26 (23%) set no upper age limit and 76 (67%) stop at 75 or younger; 1 takes children under 18; 13 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 3 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 72 is above the median of 59 across 372 interventional studies indexed under Depressive Disorder, Treatment-Resistant.
Median enrollment 139 across the 21 interventional studies, 500 across the 5 observational. Of the 15 that completed or were terminated, 6 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 26 have an industry lead sponsor. The 10 most frequent:
This study is registered under Beckley Psytech Limited, one of the names counted as Eli Lilly and Company. Under that name alone:
Beckley Psytech Limited is the lead sponsor of 6 studies on the registry; 1 is open to participants now.
Eli Lilly and Company has 5 studies filed under Depressive Disorder, Treatment-Resistant — fewer than ten, so there is no comparison to draw.
2 of the studies in Depressive Disorder, Treatment-Resistant with a site in United Kingdom that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05660642Beckley Psytech LimitedAn Open-Label Study to Evaluate the Safety, Tolerability and Pharmacodynamics of BPL-003 in Patients With Treatment Resistant Depression | 2026-11 |
| NCT07553637Alto NeuroscienceALTO-207 in Adults With Treatment-resistant Depression (TRD) | 2027-11 |
Add all 2 to your calendar (.ics) → With an account.
Among the 26 studies in Depressive Disorder, Treatment-Resistant with a site in United Kingdom, from their registry updates:
This tab as a report to print or save as PDF → With an account.
An open-label, multi-centre, Phase 2a study to evaluate the safety, tolerability, and pharmacodynamics of one and two doses of intranasal BPL-003 combined with psychological support, in patients with treatment resistant depression when administered as monotherapy or as adjunctive therapy with defined SSRIs (citalopram, escitalopram, sertraline or fluoxetine).
Part 1: Up to 32 patients, across 2 parallel arms (Arms A and Arms B) will receive one of two single doses of BPL-003, given intranasally, with 12 weeks of follow-up assessments.
Part 2: Up to 40 patients, across 2 parallel arms (Arms A and Arms B) will receive two doses of BPL-003, given intranasally, with 10 weeks of follow-up assessments.
Psychological support will be given before, during and after dosing in Part 1 and Part 2.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: BPL-003
Drug: BPL-003
Experimental BPL-003 arms: will investigate one of two doses of BPL-003 (Part 1) and two doses of BPL-003 (Part 2)
1. To assess the safety and tolerability of single or multiple intranasal doses of BPL-003 in patients with treatment resistant depression
* Percentage of patients with treatment emergent adverse events * Percentage of patients with clinically significant abnormal laboratory tests * Percentage of patients with clinically significant abnormal vital signs * Percentage of patients with clinically significant findings in physical examination * Percentage of patients with clinically significant ECG parameters or cardiac telemetry abnormalities (Part 1 Arm B only) * Percentage of patients with suicidal ideation or behaviour
Time frame: Baseline to 12 weeks post dose
Change from Baseline in MADRS
Time frame: Day 2 to 12 weeks post dose
Percentage of responders
Defined as 50% reduction in MADRS score compared to Baseline
Time frame: Day 2 to 12 weeks post dose
Percentage of patients in remission
Defined as MADRS score of \<11
Time frame: Day 2 to 12 weeks post dose
Plasma levels of 5-MeO-DMT and its metabolites
Time frame: Day 1
Not enrolling at this site.
Plan to share: No — Due to the UK GDPR, individual participant data will not be shared publicly. Group data will be presented in publication after study completion.
No publications or documents are linked to this record.
Started Feb 2023 (actual). Primary completion is estimated for Nov 2026, 45 months after the start.
Of 50 phase 2 interventional studies under Depressive Disorder, Treatment-Resistant, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 41. This study's planned 45 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: BPL-003
Depressive Disorder, Treatment-Resistant →